A Study of End of Dose Phenomena in Subcutaneous Natalizumab Treated Multiple Sclerosis (MS) Participants

NCT05701423 · clinicaltrials.gov ↗
TERMINATED
Status
34
Enrollment
INDUSTRY
Sponsor class

Stopped Due to low enrolment the sponsor decided to terminate the study

Conditions

Interventions

Sponsor

Biogen